We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Peter Rossing

Peter Rossing MD, DMSc

Head of Complications Research, Chief Physician, Steno Diabetes Center, Copenhagen, Denmark
Peter Rossing is a clinician researcher devoted to complications in diabetes with focus on renal and cardiovascular complications. He obtained a specialist degree in internal medicine and endocrinology 2004. Since 2007 he has been a chief physician and manager of the Steno Diabetes Center research team dedicated to the research of micro-and macrovascular complications of diabetes.

Since 2012 Professor in diabetic angiopathy at University of Copenhagen. Peter Rossing has in epidemiological studies investigated key features of the pathophysiology of the diabetic kidney at different stages. He has identified several markers for development of diabetic nephropathy; making it possible to predict the individual risk. He has been involved in several intervention studies in patients with overt diabetic nephropathy aiming at improving the prognosis.

He is coordinator of the EU FP7 project PRIORITY aiming to test if urinary proteomics can be used to stratify prevention of renal complications in type 2 diabetes, and the Novo Nordisk Foundation grant PROTON aiming at personalising prevention of diabetic nephropathy.

He has co-authored >350 papers and his h-index is 65. He received the Minkowski prize in 2005 and the Golgi prize in 2016 both from the EASD. Past president of the Danish Endocrine Society, and of the European Diabetic Nephropathy Study group and chairman of the Danish National Diabetes Registry.

Disclosures

Dr. Rossing reports the following relevant disclosures: grants from Novo Nordisk and Astra Zeneca, advisory boards in Astra Zeneca, Bayer, Boehringer, Eli Lilly, Mundi, Novo Nordisk, Sanofi, Astellas, Abbvie (all fees to institution. Shares in Novo Nordisk.